There are several pipeline items in the half year releases that sound very promising and I hadn't seen in prior announcements...
Gamma camera PSMA product (ie allows prostate cancer staging in places that do not have a PET camera).
Radiomuclide therapy for multiple myeloma (alpha therapy so much much more effective)
Expanded role for the TLX-250cdx PET tracer for non-RCC cancer
novel use of PSMA bound to a visible dye so that surgeons can literally see fluorescent light showing the prostate cancer during the op.
PSMA based alpha therapy for metastatic prostate cancer.
A lot of novel and great ideas coming up!!
Great also to see a lot of Australian involvement in the pipeline. Australia is one of the leading nations for pushing the boundaries of theranostics / radionuclide therapy.
Ann: Half Year Shareholder Update, page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.11 |
Change
-0.365(1.87%) |
Mkt cap ! $6.351B | |||
| Open | High | Low | Value | Volume |
| $19.41 | $19.46 | $18.81 | $30.02M | 1.575M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1830 | $19.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.11 | 1341 | 16 |
View Market Depth
| Last trade - 15.31pm 19/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |